It's time for employers to consider more than just the medical benefits but the pharmacy benefits when it comes to specialty pharmaceuticals, said Cheryl Larson, BA, vice president of the Midwest Business Group on Health.
It’s time for employers to consider more than just the medical benefits but the pharmacy benefits when it comes to specialty pharmaceuticals, said Cheryl Larson, BA, vice president of the Midwest Business Group on Health.
She added that “robust” plan designs that concentrate on transparency and include case management and adherence programs are critical to an employer’s so-called success when dealing with specialty medications.
“Now it’s more important than ever for [employers] to understand how they do business so that they can best manage cost and again patient outcomes,” Ms Larson explained.
Dr Terrance Mayes and Dr Loretta Erhunmwunsee Discuss Leadership Roles for NCCN Forum on Equity
January 31st 2023Terrance Mayes, EdD, and Loretta Erhunmwunsee, MD, FACS, discuss their new roles as chair and vice-chair, respectively, of the National Comprehensive Cancer Network’s (NCCN) new Diversity, Equity, & Inclusion (DEI) Directors Forum.
Read More
Promoting Health Equity and Resiliency in Trauma-Affected Communities
January 31st 2023On this episode of Managed Care Cast, we speak with Reverend Paul Abernathy, CEO of the Neighborhood Resilience Project and board member of UPMC for You, who discusses his experiences in promoting health and resiliency in trauma-affected communities, as well as challenges related to access and accessibility of care and medical mistrust.
Listen
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
January 27th 2023The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
Read More
2 Clarke Drive
Cranbury, NJ 08512